Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meinardi, M. T.
Right arrow Articles by Sleijfer, D. Th.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meinardi, M. T.
Right arrow Articles by Sleijfer, D. Th.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 18, Issue 8 (April), 2000: 1725-1732
© 2000 American Society for Clinical Oncology

Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer

By M. T. Meinardi, J. A. Gietema, W. T. A. van der Graaf, D. J. van Veldhuisen, M. A. Runne, W. J. Sluiter, E. G. E. de Vries, P. B. H. Willemse, N. H. Mulder, M. P. van den Berg, H. Schraffordt Koops, D. Th. Sleijfer

From the Division of Medical Oncology and Departments of Internal MedicineCardiology, Endocrinology, and Surgical Oncology, University Hospital Groningen, Groningen, the Netherlands.

Address reprint requests to J.A. Gietema, MD, PhD, Division of Medical Oncology, Department of Internal Medicine, University Hospital, PO Box 30.001, 9700 RB Groningen, the Netherlands; email j.a.gietema{at}int.azg.nl

PURPOSE: To determine whether long-term survivors of metastatic testicular cancer have an increased risk of cardiovascular morbidity more than 10 years after chemotherapy.

PATIENTS AND METHODS: Eighty-seven patients treated with cisplatin-containing chemotherapy before 1987 who were in remission for at least 10 years and whose ages were <= 50 years at the time of analysis were evaluated for the occurrence of cardiovascular events. Sixty-two of 87 patients were additionally evaluated for cardiac damage and cardiovascular risk factors. Their cardiovascular risk profile was compared with that of 40 patients with comparable age and follow-up duration treated with orchidectomy only for stage I disease.

RESULTS: Major cardiac events were found in five (6%) of the 87 patients (age at time of event, 30 to 42 years; time after chemotherapy, 9 to 16 years): two with myocardial infarction and three with angina pectoris with proven myocardial ischemia. An increased observed-to-expected ratio of 7.1 (95% confidence interval, 1.9 to 18.3) for coronary artery disease, as compared with the general male Dutch population, was found. In addition, one patient experienced a cerebrovascular accident. Exercise ECG did not reveal cases of subclinical coronary artery disease. Echocardiography showed normal systolic left ventricular function in most patients, but diastolic left ventricular function was disturbed in 33% of the patients. Of 62 chemotherapy patients, 79% had hypercholesterolemia, 39% had hypertension, 25% still experienced Raynaud’s phenomenon, and 22% had microalbuminuria. Compared with patients with stage I disease, the chemotherapy patients had higher blood pressure and higher total cholesterol and triglyceride levels and were more insulin-resistant.

CONCLUSION: In long-term survivors of metastatic testicular cancer, we observed a significantly increased risk for occurrence of cardiac events accompanied by a persisting unfavorable cardiovascular risk profile. Accurate follow-up, focused on cardiovascular complications and aimed at intervention in these young cancer survivors, seems to be important.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. T. Nguyen, A. Z. Fu, T. D. Gilligan, B. J. Wells, E. A. Klein, M. W. Kattan, and A. J. Stephenson
Defining the Optimal Treatment for Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer Using Decision Analysis
J. Clin. Oncol., January 1, 2010; 28(1): 119 - 125.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Brydoy, J. Oldenburg, O. Klepp, R. M. Bremnes, E. A. Wist, T. Wentzel-Larsen, E. R. Hauge, O. Dahl, and S. D. Fossa
Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors
J Natl Cancer Inst, December 16, 2009; 101(24): 1682 - 1695.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
B. MELICHAR, H. KALABOVA, L. KRCMOVA, M. KASPAROVA, E. MALIROVA, K. MELICHAROVA, M. PECKA, R. HYSPLER, and D. SOLICHOVA
Serum Homocysteine, Cholesterol, Retinol, {alpha}-Tocopherol, Glycosylated Hemoglobin and Inflammatory Response during Therapy with Bevacizumab, Oxaliplatin, 5-Fluorouracil and Leucovorin
Anticancer Res, November 1, 2009; 29(11): 4813 - 4820.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Kollmannsberger, C. Moore, K. N. Chi, N. Murray, S. Daneshmand, M. Gleave, B. Hayes-Lattin, and C.R. Nichols
Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy
Ann. Onc., October 29, 2009; (2009) mdp473v1.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pediatric Oncology NursingHome page
D. Eshelman-Kent, E. Gilger, and M. Gallagher
Transitioning Survivors of Central Nervous System Tumors: Challenges for Patients, Families, and Health Care Providers
Journal of Pediatric Oncology Nursing, September 1, 2009; 26(5): 280 - 294.
[Abstract] [PDF]

Home page
 JCOHome page
T. Tandstad, O. Dahl, G. Cohn-Cedermark, E. Cavallin-Stahl, U. Stierner, A. Solberg, C. Langberg, R. M. Bremnes, A. Laurell, H. Wijkstrom, et al.
Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program
J. Clin. Oncol., May 1, 2009; 27(13): 2122 - 2128.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. C. Gilbert, N. J. VanAs, S. Beesley, D. Bloomfield, J. Money-Kyrle, A. Norman, D. Dearnaley, A. Horwich, and R. A. Huddart
Treating IIA/B Seminoma With Combination Carboplatin and Radiotherapy
J. Clin. Oncol., April 20, 2009; 27(12): 2101 - 2102.
[Full Text] [PDF]

Home page
 JCOHome page
J. Sheinfeld and R. J. Motzer
Stage I Testicular Cancer Management and Necessity for Surgical Expertise
J. Clin. Oncol., June 20, 2008; 26(18): 2934 - 2936.
[Full Text] [PDF]

Home page
 Ann OncolHome page
T. Powles, D. Robinson, J. Shamash, H. Moller, N. Tranter, and T. Oliver
The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis
Ann. Onc., March 1, 2008; 19(3): 443 - 447.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Stephenson, G. J. Bosl, R. J. Motzer, D. F. Bajorin, J. P. Stasi, and J. Sheinfeld
Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer
J. Clin. Oncol., December 10, 2007; 25(35): 5597 - 5602.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. Bajorin
The Graying of Testis Cancer Patients: What Have We Learned?
J. Clin. Oncol., October 1, 2007; 25(28): 4341 - 4343.
[Full Text] [PDF]

Home page
 JCOHome page
R. de Wit
Refining the Optimal Chemotherapy Regimen in Good Prognosis Germ Cell Cancer: Interpretation of the Current Body of Knowledge
J. Clin. Oncol., October 1, 2007; 25(28): 4346 - 4349.
[Full Text] [PDF]

Home page
 JCOHome page
A. W. van den Belt-Dusebout, R. de Wit, J. A. Gietema, S. Horenblas, M. W.J. Louwman, J. G. Ribot, H. J. Hoekstra, G. M. Ouwens, B. M.P. Aleman, and F. E. van Leeuwen
Treatment-Specific Risks of Second Malignancies and Cardiovascular Disease in 5-Year Survivors of Testicular Cancer
J. Clin. Oncol., October 1, 2007; 25(28): 4370 - 4378.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. S. Kaufman, M. A. Saksena, R. H. Young, and S. Tabatabaei
Case 6-2007 -- A 28-Year-Old Man with a Mass in the Testis
N. Engl. J. Med., February 22, 2007; 356(8): 842 - 849.
[Full Text] [PDF]

Home page
 Ann OncolHome page
H. Haugnes, N Aass, S. Fossa, O Dahl, O Klepp, E. Wist, J Svartberg, T Wilsgaard, and R. Bremnes
Components of the metabolic syndrome in long-term survivors of testicular cancer
Ann. Onc., February 1, 2007; 18(2): 241 - 248.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. de Haas, D. Th. Sleijfer, and J. Gietema
Follow-up of successfully treated testicular cancer patients: consequences of the metabolic syndrome
Ann. Onc., February 1, 2007; 18(2): 211 - 212.
[Full Text] [PDF]

Home page
 JCOHome page
R. de Wit and K. Fizazi
Controversies in the Management of Clinical Stage I Testis Cancer
J. Clin. Oncol., December 10, 2006; 24(35): 5482 - 5492.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. V. Kondagunta and R. J. Motzer
Chemotherapy for Advanced Germ Cell Tumors
J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Ganz
Monitoring the Physical Health of Cancer Survivors: A Survivorship-Focused Medical History
J. Clin. Oncol., November 10, 2006; 24(32): 5105 - 5111.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Compr Canc NetwHome page
E. Efstathiou and C. J. Logothetis
Review of Late Complications of Treatment and Late Relapse in Testicular Cancer
J Natl Compr Canc Netw, November 1, 2006; 4(10): 1059 - 1070.
[Abstract] [PDF]

Home page
 JCOHome page
E. C. de Haas, J. Nuver, M. P. van den Berg, A. J. Smit, D. Th. Sleijfer, and J. A. Gietema
In Reply
J. Clin. Oncol., July 20, 2006; 24(21): 3508 - 3509.
[Full Text] [PDF]

Home page
 JCOHome page
P. J. Loehrer and G. J. Bosl
In Reply
J. Clin. Oncol., June 20, 2006; 24(18): e32 - e33.
[Full Text] [PDF]

Home page
 JCOHome page
T. Gilligan, W. K. Oh, and P. W. Kantoff
Carboplatin for Stage I Seminoma
J. Clin. Oncol., June 20, 2006; 24(18): 2971 - 2972.
[Full Text] [PDF]

Home page
 JCOHome page
G. V. Kondagunta, R. J. Motzer, G. J. Bosl, and J. Sheinfeld
IN REPLY
J. Clin. Oncol., June 1, 2006; 24(16): 2598 - 2599.
[Full Text] [PDF]

Home page
 JCOHome page
A. W. van den Belt-Dusebout, J. Nuver, R. de Wit, J. A. Gietema, W. W. ten Bokkel Huinink, P. T.R. Rodrigus, E. C. Schimmel, B. M.P. Aleman, and F. E. van Leeuwen
Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer
J. Clin. Oncol., January 20, 2006; 24(3): 467 - 475.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Nuver, A. J. Smit, J. van der Meer, M. P. van den Berg, W. T.A. van der Graaf, M. T. Meinardi, D. Th. Sleijfer, H. J. Hoekstra, A. I. van Gessel, A. M. van Roon, et al.
Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer
J. Clin. Oncol., December 20, 2005; 23(36): 9130 - 9137.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Steingart
Mechanisms of Late Cardiovascular Toxicity From Cancer Chemotherapy
J. Clin. Oncol., December 20, 2005; 23(36): 9051 - 9052.
[Full Text] [PDF]

Home page
 JCOHome page
P. J. Loehrer Sr and G. J. Bosl
Carboplatin for Stage I Seminoma and the Sword of Damocles
J. Clin. Oncol., December 1, 2005; 23(34): 8566 - 8569.
[Full Text] [PDF]

Home page
 JCOHome page
H. Sagstuen, N. Aass, S.D. Fossa, O. Dahl, O. Klepp, E.A. Wist, T. Wilsgaard, and R.M. Bremnes
Blood Pressure and Body Mass Index in Long-Term Survivors of Testicular Cancer
J. Clin. Oncol., August 1, 2005; 23(22): 4980 - 4990.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Nuver, A. J. Smit, B. H.R. Wolffenbuttel, W. J. Sluiter, H. J. Hoekstra, D. T. Sleijfer, and J. A. Gietema
The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular Cancer
J. Clin. Oncol., June 1, 2005; 23(16): 3718 - 3725.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Raghavan
Hidden by HIPAA: The Costs of Cure
J. Clin. Oncol., June 1, 2005; 23(16): 3663 - 3665.
[Full Text] [PDF]

Home page
 JCOHome page
A. J. Stephenson, G. J. Bosl, R. J. Motzer, M. W. Kattan, J. Stasi, D. F. Bajorin, and J. Sheinfeld
Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome
J. Clin. Oncol., April 20, 2005; 23(12): 2781 - 2788.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Gilligan
Retroperitoneal lymph node dissection versus chemotherapy for stage I testicular nonseminomas
Ann. Onc., January 1, 2005; 16(1): 172 - 173.
[Full Text] [PDF]

Home page
 CirculationHome page
E. T.H. Yeh, A. T. Tong, D. J. Lenihan, S. W. Yusuf, J. Swafford, C. Champion, J.-B. Durand, H. Gibbs, A. A. Zafarmand, and M. S. Ewer
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Circulation, June 29, 2004; 109(25): 3122 - 3131.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Zagars, M. T. Ballo, A. K. Lee, and S. S. Strom
Mortality After Cure of Testicular Seminoma
J. Clin. Oncol., February 15, 2004; 22(4): 640 - 647.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Horwich
Radiotherapy in Stage I Seminoma of the Testis
J. Clin. Oncol., February 15, 2004; 22(4): 585 - 588.
[Full Text] [PDF]

Home page
 JCOHome page
Y. Vergouwe, E. W. Steyerberg, M. J.C. Eijkemans, P. Albers, and J. D. F. Habbema
Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review
J. Clin. Oncol., November 15, 2003; 21(22): 4092 - 4099.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
Oral Presentation Abstracts
J. Nutr., November 1, 2003; 133(11): 3843S - 3850.
[Full Text] [PDF]

Home page
 JCOHome page
R.A. Huddart and A. Norman
In Reply:
J. Clin. Oncol., October 15, 2003; 21(20): 3888 - 3889.
[Full Text] [PDF]

Home page
 JCOHome page
R.A. Huddart, A. Norman, M. Shahidi, A. Horwich, D. Coward, J. Nicholls, and D.P. Dearnaley
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
J. Clin. Oncol., April 15, 2003; 21(8): 1513 - 1523.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. J. Vaughn, G. A. Gignac, and A. T. Meadows
Long-Term Medical Care of Testicular Cancer Survivors
Ann Intern Med, March 19, 2002; 136(6): 463 - 470.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Fizazi, I. Chen, and C. J. Logothetis
Germ-cell tumor survivors: the price for cure
Ann. Onc., February 20, 2002; 13(2): 187 - 189.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. D. Fossa, N. Aass, M. Winderen, O. P. Bormer, and D. R. Olsen
Long-term renal function after treatment for malignant germ-cell tumours
Ann. Onc., February 20, 2002; 13(2): 222 - 228.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Strumberg, S. Brugge, M. W. Korn, S. Koeppen, J. Ranft, G. Scheiber, C. Reiners, C. Mockel, S. Seeber, and M. E. Scheulen
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer
Ann. Onc., February 20, 2002; 13(2): 229 - 236.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Vaughn and A. T. Meadows
Cancer Survivorship Research: The Best Is Yet to Come
J. Clin. Oncol., February 15, 2002; 20(4): 888 - 890.
[Full Text] [PDF]

Home page
 JCOHome page
L. D.A. Dorresteijn, A. C. Kappelle, W. Boogerd, W. J. Klokman, A. J.M. Balm, R. B. Keus, F. E. van Leeuwen, and H. Bartelink
Increased Risk of Ischemic Stroke After Radiotherapy on the Neck in Patients Younger Than 60 Years
J. Clin. Oncol., January 1, 2002; 20(1): 282 - 288.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
D. Dearnaley, R. Huddart, and A Horwich
Regular review: Managing testicular cancer
BMJ, June 30, 2001; 322(7302): 1583 - 1588.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online